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Abstract
Background: Reported associations of male circumcision (MC) with human papillomavirus (HPV) infection in men
have been inconsistent.
Methods: 4,033 healthy men were examined every six months for a median of 17.5 months. In each study visit,
exfoliated cell specimens from the coronal sulcus/glans penis, penile shaft, and scrotum were collected and
combined into one sample per person for HPV DNA detection. Samples were tested for 37 HPV types. Cox
proportional hazards models were used to evaluate the association between MC and the incidence and clearance
of HPV infections and specific genotypes.
Results: The overall incidence of new HPV infections did not differ by MC status (for any HPV, adjusted hazard ratio
(aHR) 1.08, 95% confidence interval (CI) 0.91-1.27). However, incidence was significantly lower among circumcised
versus uncircumcised men for HPV types 58 (p = 0.01), 68 (p < 0.001), 42 (p = 0.01), 61 (p < 0.001), 71 (p < 0.001), 81
(p = 0.04), and IS39 (p = 0.01), and higher for HPV types 39 (p = 0.01) and 51 (p = 0.02). Despite the lack of an overall
association in the risk of HPV clearance by MC (for any HPV, aHR 0.95, 95% CI 0.88-1.02), median times to clearance
were significantly shorter among circumcised than uncircumcised men for HPV types 33 (p = 0.02) and 64 (p = 0.04),
and longer for HPV types 6 (p < 0.001), 16 (p < 0.001), and 51 (p = 0.02).
Conclusions: MC is not associated with the incidence and clearance of genital HPV detection, except for certain
HPV types. The use of a single combined sample from the penis and scrotum for HPV DNA detection likely limited
our ability to identify a true effect of MC at the distal penis.
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Background
The majority of sexually active men and women will ac-
quire genital human papillomavirus (HPV) infection at
some point during their lifetime. In 2008, an estimated
610,000 cancers in men and women were attributed to
HPV infection worldwide [1]. The natural history of cer-
vical HPV infection is well characterized; however, little
is known about genital HPV infection in men. A recent
randomized controlled trial (RCT) of male circumcision
(MC) in Uganda (Africa) showed that MC reduced the
incidence of high-risk HPV (HR-HPV) infections and in-
creased clearance of HR-HPV infections at the coronal
sulcus [2]. However, findings regarding the role of MC
in the incidence and clearance of genital HPV infections
have not been consistent across studies [3-5].
Our previously published data regarding the preva-
lence of genital HPV among all men enrolled in the
HPV Infection in Men (HIM) Study showed no overall
association between MC and genital HPV infections,
except for certain HPV types [6]. The purpose of this
study was to determine whether MC affects the inci-
dence and clearance of genital HPV infections in a* Correspondence: Anna.Giuliano@moffitt.org
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large, multinational cohort study of healthy men in
Brazil, Mexico, and the United States (USA).
Methods
Study population
From June 2005 through September 2009, healthy men
were enrolled in an ongoing longitudinal study of HPV
infection in men, the HIM cohort study. Men were
recruited from the general population, universities, and
organized health-care systems. Details of the study have
been previously described [7]. In brief, men were in-
cluded if they 1) were aged 18–70 years, 2) were resi-
dents of southern Florida, USA, Cuernavaca, Mexico, or
São Paulo, Brazil, 3) had no prior diagnosis of penile or
anal cancer, 4) had no prior diagnosis of genital or anal
warts, 5) had no current diagnosis or symptoms of sexu-
ally transmitted infections (STIs), 6) had not participated
in an HPV vaccine study, 7) reported no previous diag-
nosis of HIV, 8) had not been imprisoned, homeless, or
received drug treatment during the past six months, 9)
were willing to commit to 10 scheduled visits every six
months, and 10) had no plans to relocate within the next
four years. Men who were eligible to participate reviewed
and signed a written informed consent form. Before study
initiation, the Human Subjects Committees of the
University of South Florida, the Centro de Referencia e
Tratamento de Doencas Sexualmente Transmissiveis e
AIDS, Brazil, and The National Institute of Public
Health of Mexico approved the research protocol.
Consenting participants completed a pre-enrollment
visit, an enrollment visit scheduled approximately two
weeks later, and eight additional visits after enrollment
that occurred every six months over a period of four
years. At each study visit, participants completed an
88-item computer-assisted self-interview (CASI) which
collected information regarding sociodemographic char-
acteristics, tobacco consumption, and sexual behavior.
The primary languages spoken by participants from
Brazil, Mexico, and the United States were Portuguese,
Spanish, and English, respectively, and the CASI was
available in these languages. After the interview, men
underwent a clinical examination at which time circum-
cision status was assessed. Participants with full or par-
tial circumcision were considered circumcised.
Penile and scrotal sampling
Sampling techniques have been described in detail previ-
ously [8]. Briefly, exfoliated epithelial cells from the cor-
onal sulcus/glans penis, penile shaft, and scrotum were
collected using three different saline pre-wetted Dacron
swabs and combined into one sample before DNA ex-
traction. Among uncircumcised men, the foreskin was
sampled at the time of collecting the coronal sulcus/
glans penis specimen. All HPV samples were stored
at −80°C prior to polymerase chain reaction (PCR) ana-
lysis and genotyping. These sampling procedures were
standardized across the three countries, with one clinical
site per country. Staff at each site collecting specimens
and conducting physical exams were either medical doc-
tors or nurse practitioners.
HPV analyses
The detailed protocol for HPV analysis has been previ-
ously described [8]. Briefly, DNA was extracted using
the Media Kit (QIAGen, Valencia, CA, USA), according
to the manufacturer’s instructions. HPV testing was
undertaken by use of PCR for amplification of a frag-
ment of the HPV L1 gene. Specimens were tested for
the presence of HPV with the PGMY09/11 L1 consensus
primer system [9]. HPV genotyping was conducted on
all specimens, regardless of the HPV PCR result, using
the Linear Array method (Roche Molecular Diagnostics,
Alameda, CA, USA) [10] to detect 37 HPV types. The
13 HPV types classified as oncogenic included: 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Non-
oncogenic HPV types: 6, 11, 26, 40, 42, 53, 54, 55, 61,
62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and
89 (CP6108) [11]. Samples were considered valid if they
were positive for β-globin and/or any HPV DNA genotype.
Statistical analysis
Differences in the distribution of sociodemographic
characteristics, tobacco consumption, and sexual behav-
ior characteristics by circumcision status were compared
using the Pearson’s chi-square test. Differences in the
median time to follow-up by MC status were compared
using a nonparametric equality of medians test.
The classification of “any HPV” was defined as a positive
test result for at least one of the 37 HPV genotypes in-
cluded in the Linear Array test. HPV detection of single or
multiple oncogenic HPV types was classified as “oncogenic
HPV”. Similarly, HPV detection of single or multiple non-
oncogenic HPV types was classified as “non-oncogenic
HPV”.
HPV incidence by circumcision status was estimated
according to different classifications of HPV types: any
HPV, oncogenic HPV, non-oncogenic HPV, and for each
specific HPV type. For each of the above analyses, only
participants free of the relevant HPV type at enrollment
were included. Men with concomitant incident HPV in-
fections could contribute to several HPV classifications.
Time to newly acquired HPV was estimated using the
time from the date of study entry to the date of the first
detection of HPV DNA, assuming a new infection arose
at the date of detection. The exact 95% confidence
intervals (CIs) for incidence estimates were based on
the number of events modeled as a Poisson variable for
the total person-months. The unit of observation was
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the individual participant, and each man with an inci-
dent HPV infection was counted only once during
follow-up using only data from the first occurrence.
Cumulative incidence of any HPV, HPV 16, oncogenic
HPV, and non-oncogenic HPV types was estimated for
circumcised and uncircumcised men using the Kaplan-
Meier method.
Cox proportional hazards models were used to assess
the association between HPV incidence and circumci-
sion status [12]. Hazards ratios (HRs) and 95% CIs were
used as measures of association for comparison of cir-
cumcised versus uncircumcised men. The proportional
hazards assumption for the Cox models was tested
[13], and no violations were found, except in the non-
oncogenic HPV model. The non-oncogenic HPV inci-
dence model was stratified according to age to reduce
violations of the proportional hazards assumption.
HPV clearance was defined as a participant testing
HPV negative at two subsequent consecutive visits fol-
lowing a positive HPV test result, excluding those testing
HPV positive for the first time at a participant’s final
visit. Time to HPV clearance was estimated by using the
time at which the participant first tested positive to the
date of the first negative test. Median time to clearance
was estimated among incident infections using the
Kaplan-Meier method for any HPV, oncogenic HPV,
non-oncogenic HPV, and for each specific HPV type,
according to circumcision status. Analyses were per-
formed for each individual HPV type. Men whose HPV
infections did not clear were censored in the analysis.
Cox proportional hazards models with the robust co-
variance matrix estimator to account for within-subject
correlation were used to assess the association between
HPV clearance and circumcision status [12]. Men with
HPV infections, regardless of baseline HPV status, were
included in the models. HRs and 95% CIs were used as
measures of association for the comparison of circum-
cised versus uncircumcised men. The proportional haz-
ards assumption for the Cox models was tested [13], and
HPV clearance models were stratified according to age
and country to reduce violations of the proportional
hazards assumption.
An HPV infection was considered persistent if a man
was HPV DNA-positive at two or more consecutive
visits with the same specific HPV type, and an HPV in-
fection was considered transient if a man was positive
only once. When a participant missed a study visit, the
results from the next visit were used.
The same variable selection procedure was used to
evaluate factors associated with incidence and clearance
of HPV infections. Factors that had a p-value < 0.10 were
considered covariates. Backwards selection methods, with
a significance threshold of 0.05, were used to identify
covariates for inclusion in the final multivariable model.
Candidate variables included education, marital status,
smoking status, lifetime number of female sexual partners,
lifetime number of male anal sex partners, number of fe-
male sexual partners in the past 3–6 months, number of
male anal sex partners in the past 3 months, and six-
month visit compliance status (i.e. whether the elapsed
time between follow-up visits was longer than 6.5 months).
Country (USA, Brazil, and Mexico) and age (categorical)
were included in all models as study design factors. In
addition, HPV status at baseline was a candidate variable
in the HPV clearance models.
Statistical analyses were conducted using R 2.13.0 (R
Development Core Team) and SAS software, version 9.2
(SAS Institute Inc., Cary, NC). Statistical tests were two-
sided, with a significance threshold of 0.05.
Results
Of the 4,074 initial HIM Study participants, 4,033 con-
tributed valid samples for HPV DNA detection and were
included in the analyses. Thus, 19 circumcised and 22
uncircumcised men (chi-square p-value = 0.03) contrib-
uted inadequate samples, as determined by both lack of
β-globin detection and absence of any HPV genotype.
The median duration of follow-up was 17.5 months
(interquartile range [IQR], 6.9 – 31.0 months) for this
analysis. There were no significant differences in the me-
dian duration of follow-up for circumcised (17.9 months)
versus uncircumcised men (17.1 months) (p = 0.5 for
nonparametric equality of medians test). More than 60%
of men contributed at least 4 visits (IQR, 3 – 6 visits).
The majority of men were uncircumcised (63.6%) (Table 1).
Sociodemographic and behavioral characteristics of men
varied by circumcision status. Circumcised men were
generally younger (mean age: 31 vs. 33 years) and were
residents of the USA (72.7%). Statistically significant differ-
ences by circumcision status were observed for marital sta-
tus, sexual orientation, lifetime number of female sexual
partners, number of female sexual partners in the past
3–6 months, lifetime number of male sexual partners,
number of male anal sexual partners in past 3 months, self-
reported diagnosis of STIs, and six-month visit compliance
status (Table 1).
HPV incidence by MC status
Kaplan-Meier analyses showed that the overall incidence
of any HPV did not differ by circumcision status (P =
0.287, log-rank test). Similarly, incidence of HPV 16,
oncogenic HPV, and non-oncogenic HPV did not differ
by circumcision status (Figure 1). Estimates for inci-
dence per 100 person-years of any HPV, oncogenic HPV,
and non-oncogenic HPV were 50.5, 28.4, and 39.8, re-
spectively, among uncircumcised men, and 45.6, 28.7,
and 34.0, respectively, among circumcised men (Table 2).
However, the incidence of oncogenic HPV types 39, 51,
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Table 1 Baseline characteristics of participants in the study cohort
Uncircumcised N = 2564 Circumcised N = 1469
N % column N % column P-valuea
Age (years) <0.0001
Mean (SD) 33.3 (10.3) 31.0 (12.2)
18-30 1125 43.9 841 57.2
31-44 1125 43.9 421 28.7
45-70 314 12.2 207 14.1
Country of residence <0.0001
USA 247 9.6 1068 72.7
Brazil 1200 46.8 198 13.5
Mexico 1117 43.6 203 13.8
Marital status <0.0001
Single 955 37.4 861 58.7
Married 1040 40.7 332 22.6
Cohabiting 374 14.6 108 7.4
Divorced/Separated/Widowed 187 7.3 165 11.3
Current smoker 0.054
No 1931 75.5 1147 78.2
Yes 628 24.5 320 21.8
Sexual orientation <0.0001
MSW 2107 82.5 1285 87.8
MSWM 162 6.3 55 3.8
MSM 134 5.2 42 2.9
No sex 151 5.9 82 5.6
Lifetime number of female sexual partners 0.025
Median (SD) 6 (2047.3) 7 (78.2)
0 253 10.6 137 9.7
1 193 8.1 130 9.2
2-9 1044 43.6 566 39.9
10-19 423 17.7 246 17.3
20-49 355 14.8 238 16.8
50+ 124 5.2 101 7.1
Number of female sexual partners in past 3–6 months <0.0001
Mean (SD) 1.4 (2.3) 1.3 (1.7)
0 722 30.7 347 24.8
1 948 40.3 690 49.3
2 351 14.9 165 11.8
3+ 329 14.0 197 14.1
Lifetime number of male sexual partners <0.0001
Median (SD) 0 (71.1) 0 (25.9)
0 2132 84.1 1334 90.9
1 108 4.3 41 2.8
2-9 173 6.8 55 3.7
10+ 123 4.9 37 2.5
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58, and 68, and of non-oncogenic HPV types 42, 61, 71,
81 and IS39, did differ between circumcised and uncir-
cumcised participants. Incidence was significantly higher
among circumcised men than uncircumcised men for
HPV types 39 (HR 1.47, 95% CI 1.11-1.94) and 51 (HR
1.30, 95% CI 1.04-1.61). In contrast, incidence was sig-
nificantly lower among circumcised men than uncircum-
cised men for HPV types 58 (HR 0.61, 95% CI 0.43-
0.88), 68 (HR 0.56, 95% CI 0.40-0.78), 42 (HR 0.59, 95%
CI 0.38-0.90), 61 (HR 0.59, 95% CI 0.44-0.78), 71 (HR
0.37, 95% CI 0.21-0.65), 81 (HR 0.70, 95% CI 0.50-0.98),
and IS39 (HR 0.41, 95% CI 0.20-0.86). The 12-month cu-
mulative incidence of any HPV, oncogenic HPV, and
non-oncogenic HPV among uncircumcised men was
38.7%, 23.7%, and 32.5%, respectively, compared with
35.2%, 23.3%, and 28.9%, respectively, among circum-
cised men.
In univariate and multivariate analyses, no differences
in the risk of HPV incidence by circumcision status were
observed (Table 3). A total of 359 circumcised men
(48.2%) had an incident infection, compared with 555
uncircumcised men (47.3%). For any HPV, no differences
in incidence were found by circumcision status in uni-
variate and multivariate analyses (adjusted hazard ratio
[aHR] 1.08, 95% CI 0.91-1.27). Similarly, no differences
in incidence were found by circumcision status for
oncogenic HPV (aHR 1.11, 95% CI 0.94-1.31) and non-
oncogenic HPV (aHR 1.11, 95% CI 0.94-1.30). The
magnitude of the associations remained the same after
adjustment for potential confounders, including socio-
demographic characteristics and sexual behavior, or
when changing the unit of analysis from men to infec-
tion (data not shown). Results were consistent when
analyses were stratified by country of residence (data
not shown).
HPV clearance by MC status
Kaplan-Meier analyses showed that the median time
to clearance of any HPV infection was significantly lon-
ger among circumcised men than uncircumcised men
(P < 0.0001, log-rank test) (Figure 2). Similarly, median
time to clearance of oncogenic HPV and non-oncogenic
HPV types was significantly shorter among uncircumcised
men than circumcised men. Median time to clearance was
also significantly shorter among uncircumcised men than
circumcised men for HPV types 6 (HR 0.60, 95% CI 0.44-
0.81), 16 (HR 0.56, 95% CI 0.42-0.75), and 51 (HR 0.72,
95% CI 0.54-0.95) (Table 4). Correspondingly, the probabil-
ity of clearing an HPV infection was significantly lower
among circumcised men compared to uncircumcised men.
However, median time to clearance was significantly shorter
among circumcised men compared to uncircumcised men
for HPV 33 (HR 2.54, 95% CI 1.12-5.73). Although the me-
dian time to clearance for HPV 64 was significantly shorter
among circumcised versus uncircumcised men, the corre-
sponding HR did not reach statistical significance (HR 6.06,
95% CI 0.84-43.74).
Univariate and multivariate analyses for clearance are
presented in Table 5. HPV clearance was significantly
decreased for any HPV infection among circumcised
men compared to uncircumcised men in the univariate
analysis (HR 0.92, 95% CI 0.86-0.99). However, after
Table 1 Baseline characteristics of participants in the study cohort (Continued)
Number of male anal sexual partners in past 3 months 0.003
Median (SD) 0 (3.3) 0 (1.0)
None 2360 92.9 1406 95.7
1 75 3.0 25 1.7
2 31 1.2 16 1.1
3+ 73 2.9 22 1.5
Diagnosis of STIs, ever <0.0001
No 2006 81.2 1246 86.8
Yes 463 18.8 190 13.2
HPV status at baseline 0.793
Negative 847 33.0 492 33.5
Positive 1717 67.0 977 66.5
Six-month visit compliance status <0.0001
No 1584 61.8 846 57.6
Yes 980 38.2 623 42.4
aPearson’s chi-square test was used for statistical comparison between circumcised and uncircumcised men. Some categories do not sum to the total because of
missing values. Subjects with unknown values for each characteristic were not included for calculations of p-values.
NOTE: SD, standard deviation; MSW, men who have sex with women; MSWM, men who have sex with women and men; MSM, men who have sex with men, STIs,
sexually transmitted infections.
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adjustment, this difference was no longer significant
(aHR 0.95, 95% CI 0.88-1.02). Similarly, there were no
differences in the risk of clearance for oncogenic HPV
(aHR 0.90, 95% CI 0.81-1.00) or non-oncogenic HPV
(aHR 0.98, 95% CI 0.89-1.07) by circumcision status. The
magnitude of the associations with MC did not change sub-
stantially for transient (Table 6) versus persistent (Table 7)
HPV infections. Moreover, similar results were observed
when analyses were stratified by country of residence (data
not shown).
Discussion
MC was not associated with an overall reduction in the
incidence of genital HPV detection in men. Other longi-
tudinal studies also found no differences in the risk of
HPV incidence by MC [3-5]. Lu et al. [3] and Hernandez
et al. [4] used combined samples from the coronal sul-
cus, glans penis, shaft of the penis, and scrotum for
HPV detection and found no differences in HPV acquisi-
tion by MC. Although VanBuskirk et al. [5] observed
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Figure 1 Kaplan-Meier estimates of the cumulative incidence of human papillomavirus (HPV) infections. Kaplan-Meier estimates of the
cumulative incidence of human papillomavirus (HPV) infections for any HPV, oncogenic HPV, non-oncogenic HPV, and HPV 16 by male circumcision status:
A) Incidence of any HPV; B) Incidence of oncogenic HPV; C) Incidence of non-oncogenic HPV; D) Incidence of HPV 16.
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Table 2 Incidence of HPV by male circumcision status
















Any HPVa 555/1098 50.5 (46.4, 54.9) 38.7 (35.5, 41.7) 359/788 45.6 (41, 50.5) 35.2 (31.4, 38.8) 0.29 0.93 (0.81-1.06)
Oncogenicb 584/2055 28.4 (26.2, 30.8) 23.7 (21.5, 25.9) 369/1285 28.7 (25.9, 31.8) 23.3 (20.5, 26) 0.64 1.03 (0.84-1.26)
16 204/3546 5.8 (5, 6.6) 5.1 (4.1, 6) 143/2164 6.6 (5.6, 7.8) 6.3 (4.9, 7.7) 0.15 1.17 (0.95-1.45)
18 97/3886 2.5 (2, 3) 1.9 (1.3, 2.5) 71/2421 2.9 (2.3, 3.7) 3.1 (2.1, 4) 0.24 1.20 (0.88-1.63)
31 71/3904 1.8 (1.4, 2.3) 1.6 (1.1, 2.2) 52/2462 2.1 (1.6, 2.8) 2 (1.2, 2.8) 0.40 1.17 (0.81-1.67)
33 24/4039 0.6 (0.4, 0.9) 0.4 (0.1, 0.6) 16/2532 0.6 (0.4, 1) 0.8 (0.3, 1.2) 0.86 1.06 (0.56-2.00)
35 44/3951 1.1 (0.8, 1.5) 0.8 (0.5, 1.2) 26/2492 1 (0.7, 1.5) 1 (0.5, 1.6) 0.83 0.95 (0.58-1.55)
39 106/3800 2.8 (2.3, 3.4) 2.6 (1.9, 3.3) 95/2358 4 (3.3, 4.9) 3.4 (2.3, 4.4) 0.01 1.47 (1.11-1.94)
45 94/3876 2.4 (2, 3) 1.8 (1.2, 2.4) 62/2451 2.5 (1.9, 3.2) 2.9 (1.9, 3.8) 0.70 1.06 (0.77-1.47)
51 187/3615 5.2 (4.5, 6) 4.5 (3.6, 5.5) 142/2160 6.6 (5.5, 7.7) 6.8 (5.4, 8.3) 0.02 1.30 (1.04-1.61)
52 164/3525 4.7 (4, 5.4) 5.4 (4.4, 6.4) 98/2277 4.3 (3.5, 5.2) 4.3 (3.1, 5.4) 0.80 0.97 (0.75-1.24)
56 79/3894 2 (1.6, 2.5) 2 (1.4, 2.7) 56/2443 2.3 (1.7, 3) 1.7 (0.9, 2.4) 0.40 1.16 (0.82-1.63)
58 104/3845 2.7 (2.2, 3.3) 2.5 (1.8, 3.1) 42/2467 1.7 (1.2, 2.3) 1.8 (1, 2.5) 0.01 0.61 (0.43-0.88)
59 165/3672 4.5 (3.8, 5.2) 3.9 (3.1, 4.8) 119/2223 5.4 (4.4, 6.4) 5 (3.7, 6.2) 0.14 1.19 (0.94-1.51)
68 143/3789 3.8 (3.2, 4.4) 3.9 (3, 4.7) 48/2393 2 (1.5, 2.7) 2.5 (1.6, 3.4) <0.001 0.56 (0.40-0.78)
Non-oncogenicc 596/1497 39.8 (36.7, 43.1) 32.5 (29.7, 35.1) 372/1094 34 (30.6, 37.6) 28.9 (25.7, 32) 0.08 0.83 (0.69-1.00)
6 201/3553 5.7 (4.9, 6.5) 5.4 (4.4, 6.3) 104/2258 4.6 (3.8, 5.6) 3.9 (2.8, 5) 0.11 0.82 (0.65-1.04)
11 58/3961 1.5 (1.1, 1.9) 1.2 (0.7, 1.7) 25/2511 1 (0.6, 1.5) 1 (0.4, 1.5) 0.12 0.69 (0.43-1.10)
26 21/4050 0.5 (0.3, 0.8) 0.3 (0.1, 0.6) 6/2541 0.2 (0.1, 0.5) 0.5 (0.1, 0.8) 0.08 0.45 (0.18-1.12)
40 65/3941 1.6 (1.3, 2.1) 1.1 (0.6, 1.5) 44/2479 1.8 (1.3, 2.4) 1.7 (1, 2.4) 0.72 1.07 (0.73-1.58)
42 78/3914 2 (1.6, 2.5) 1.8 (1.2, 2.4) 29/2494 1.2 (0.8, 1.7) 0.8 (0.3, 1.3) 0.01 0.59 (0.38-0.90)
53 198/3630 5.5 (4.7, 6.3) 4.6 (3.7, 5.6) 110/2276 4.8 (4, 5.8) 4.4 (3.2, 5.5) 0.34 0.89 (0.71-1.13)
54 135/3815 3.5 (3, 4.2) 3.8 (2.9, 4.6) 90/2390 3.8 (3, 4.6) 3.6 (2.5, 4.6) 0.56 1.08 (0.83-1.42)
55 85/3873 2.2 (1.8, 2.7) 1.8 (1.2, 2.4) 66/2434 2.7 (2.1, 3.4) 2.5 (1.6, 3.3) 0.16 1.26 (0.91-1.74)
61 177/3628 4.9 (4.2, 5.7) 5 (4, 5.9) 68/2437 2.8 (2.2, 3.5) 3.2 (2.2, 4.2) <0.001 0.59 (0.44-0.78)
62 199/3482 5.7 (4.9, 6.6) 5.6 (4.6, 6.6) 120/2231 5.4 (4.5, 6.4) 5.3 (4, 6.6) 0.69 0.95 (0.76-1.20)
64 11/4067 0.3 (0.1, 0.5) 0.2 (0, 0.4) 3/2557 0.1 (0, 0.3) 0.1 (0, 0.2) 0.18 0.43 (0.12-1.53)
66 150/3708 4 (3.4, 4.7) 3.8 (2.9, 4.6) 112/2261 5 (4.1, 6) 5.5 (4.2, 6.8) 0.08 1.25 (0.98-1.60)
67 42/4020 1 (0.8, 1.4) 0.9 (0.5, 1.3) 22/2528 0.9 (0.5, 1.3) 0.8 (0.3, 1.3) 0.59 0.87 (0.52-1.45)




















Table 2 Incidence of HPV by male circumcision status (Continued)
70 85/3872 2.2 (1.8, 2.7) 2.3 (1.6, 2.9) 41/2467 1.7 (1.2, 2.3) 1.8 (1, 2.5) 0.20 0.78 (0.54-1.14)
71 64/3921 1.6 (1.3, 2.1) 1.7 (1.1, 2.3) 15/2531 0.6 (0.3, 1) 0.7 (0.2, 1.2) <0.001 0.37 (0.21-0.65)
72 63/3928 1.6 (1.2, 2.1) 1.6 (1.1, 2.2) 31/2503 1.2 (0.8, 1.8) 1.3 (0.7, 2) 0.31 0.80 (0.52-1.23)
73 70/3923 1.8 (1.4, 2.3) 1.5 (1, 2) 41/2478 1.7 (1.2, 2.2) 1.6 (0.9, 2.3) 0.71 0.93 (0.63-1.37)
81 113/3774 3 (2.5, 3.6) 3.2 (2.4, 3.9) 49/2447 2 (1.5, 2.6) 2.1 (1.3, 2.8) 0.04 0.70 (0.50-0.98)
82 43/4022 1.1 (0.8, 1.4) 0.7 (0.4, 1.1) 34/2487 1.4 (0.9, 1.9) 1.5 (0.8, 2.1) 0.35 1.24 (0.79-1.95)
83 78/3864 2 (1.6, 2.5) 2 (1.4, 2.6) 45/2453 1.8 (1.3, 2.5) 1.7 (1, 2.4) 0.60 0.91 (0.63-1.31)
84 225/3516 6.4 (5.6, 7.3) 6 (4.9, 7) 163/2125 7.7 (6.5, 8.9) 7.6 (6.1, 9.1) 0.09 1.19 (0.97-1.46)
89 215/3564 6 (5.3, 6.9) 5.9 (4.8, 6.9) 140/2202 6.4 (5.3, 7.5) 5.7 (4.3, 7) 0.51 1.07 (0.87-1.33)
IS39 35/4004 0.9 (0.6, 1.2) 0.6 (0.3, 1) 9/2543 0.4 (0.2, 0.7) 0.2 (0, 0.5) 0.01 0.41 (0.20-0.86)
aAny HPV was defined as at least one of 37 HPV genotypes;
bOncogenic HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68;
cNon-oncogenic HPV types: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89 (CP6108), and IS39;




















Table 3 Univariate and multivariate hazard ratios for the association between male circumcision and incidence of genital HPV infection
Any HPV Oncogenic HPV Non-Oncogenic HPV
Univariatea Multivariateb Univariatea Multivariatec Univariatea Multivariated
Circumcision Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI)
No 555/ 1174 47.3 1.00 1.00 584/ 1795 32.5 1.00 1.00 596/ 1441 41.4 1.00 1.00
Yes 359/ 745 48.2 1.08 (0.92 – 1.27) 1.08 (0.91 – 1.27) 369/ 1035 35.7 1.11 (0.94 – 1.31) 1.11 (0.94 – 1.31) 372/ 917 40.6 1.09 (0.93 – 1.28) 1.11 (0.94 – 1.30)
Total 914/ 1919 953/ 2830 968/ 2358
aAdjusted for age and country;
bAdjusted for country, age, marital status, lifetime number of female sexual partners, recent number of female sexual partners, recent number of male anal sex partners, and six-month visit compliance status;
cAdjusted for country, age, marital status, lifetime number of female sexual partners, recent number of female sexual partners, and recent number of male anal sex partners;
dCox model stratified by age and adjusted for country, marital status, lifetime number of female sexual partners, recent number of female sexual partners, lifetime number of male anal sex partners, and six-month visit
compliance status;




















found no differences in overall HPV incidence by MC at
any site (penile shaft, glans/corona, and scrotum). Our
findings are not consistent with those from a RCT con-
ducted in Uganda, which found that MC reduced the in-
cidence of HR-HPV infections (rate ratio [RR] 0.67, 95%
CI 0.50-0.90) [2]. However, this RCT was not compar-
able to our study, as they reported associations with
specimens collected from only the coronal sulcus [2].
Despite the lack of evidence for an overall association, we
did find higher HPV incidences rates in uncircumcised
men than in circumcised men for most genotypes. These
differences were statistically significant for HPV types 58,
68, 42, 61, 71, 81, and IS39. In contrast, the incidence of
oncogenic HPV types 39 and 51 were significantly higher
among circumcised than uncircumcised men. Consistent
with our study, VanBuskirk et al. [5] reported higher
HPV incidence among uncircumcised than circum-
cised men for >50% of the 21 specific HPV types
assessed. Moreover, the RCT in Uganda found that
HPV incidence was higher among uncircumcised men
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log-rank test p < 0.0001
001251322345090113Circumcised
0000136163895145Not Circumcised



































Figure 2 Kaplan-Meier estimates of time to clearance of human papillomavirus (HPV) incident infections. Kaplan-Meier estimates of time
to clearance of human papillomavirus (HPV) incident infections for any HPV, oncogenic HPV, non-oncogenic HPV, and HPV 16 by male circumcision
status: A) Clearance of any HPV; B) Clearance of oncogenic HPV; C) Clearance of non-oncogenic HPV; D) Clearance of HPV 16.
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Table 4 Clearance of HPV by male circumcision status













Median time to clearance (months;
95% CI)
Any HPVa 2973/2392 6.6 (6.4, 6.8) 1841/1480 7.1 (6.8, 7.3) <0.001 0.85 (0.80-0.91)
Oncogenicb 1129/937 6.5 (6.3, 6.8) 767/629 6.7 (6.4, 7.1) <0.001 0.83 (0.75-0.92)
16 145/118 7.1 (6.3, 8.9) 113/79 11.1 (7.2, 18.4) <0.001 0.56 (0.42-0.75)
18 71/63 6.5 (6.1, 8.1) 51/44 6.3 (6.2, 7.2) 0.84 1.04 (0.71-1.54)
31 49/39 7.2 (6.5, 14.5) 37/31 6.4 (6.1, 6.9) 0.23 1.34 (0.83-2.17)
33 16/13 6.9 (5.9, 17.6) 16/16 6 (5.8, 6.6) 0.02 2.54 (1.12-5.73)
35 34/26 11.3 (6.5, 18.1) 18/15 10.8 (7.1, N.E.) 0.86 0.95 (0.50-1.80)
39 83/66 7 (6.3, 17.3) 71/56 11.2 (7.4, 12.8) 0.68 0.93 (0.65-1.32)
45 77/65 6.3 (6.1, 10.6) 51/48 6.1 (6.1, 6.5) 0.23 1.26 (0.87-1.84)
51 144/116 6.4 (6, 7.8) 117/88 8 (6.4, 13.1) 0.02 0.72 (0.54-0.95)
52 139/119 6.4 (6, 7.6) 84/70 6.7 (6.4, 12) 0.20 0.82 (0.61-1.11)
56 58/45 6 (6, 8.9) 44/41 6.3 (6, 7.9) 0.36 1.21 (0.79-1.86)
58 72/59 6.9 (6, 11.4) 34/26 7.1 (6.2, 12.9) 0.20 0.73 (0.46-1.17)
59 122/103 6.2 (6, 6.7) 89/73 6.4 (6.2, 8.5) 0.11 0.78 (0.58-1.06)
68 119/105 6.2 (6, 6.8) 42/42 6.4 (6.2, 10.4) 0.91 0.97 (0.68-1.39)
Non-
oncogenicc
1844/1455 6.7 (6.4, 6.9) 1074/851 7.2 (6.9, 7.8) <0.001 0.86 (0.79-0.93)
6 156/142 6.1 (6, 6.4) 80/61 7.8 (6.5, 12.5) <0.001 0.60 (0.44-0.81)
11 37/27 7.8 (6.2, 14) 19/15 6.6 (6, 18.1) 0.54 1.22 (0.65-2.31)
26 17/14 6 (5.9, 7.1) 5/5 6.1 (6, N.E.) 0.62 0.76 (0.27-2.13)
40 47/41 6.4 (6, 7.8) 34/27 6.5 (6.2, 17.6) 0.09 0.66 (0.40-1.08)
42 63/53 9.1 (6.4, 12.3) 21/18 7.8 (6.2, N.E.) 0.96 1.02 (0.59-1.75)
53 150/123 6.7 (6.3, 7.8) 88/68 7.5 (6.2, 12.5) 0.10 0.78 (0.58-1.05)
54 111/86 8.3 (6.4, 12.1) 70/56 6.9 (6.4, 13.1) 0.93 1.02 (0.72-1.42)
55 67/53 7.2 (6.2, 12) 50/37 7 (6.6, 18.2) 0.20 0.76 (0.50-1.16)
61 126/89 6.5 (6.1, 8.5) 48/43 6.9 (6.4, 13.3) 0.86 0.97 (0.67-1.40)
62 148/104 7.9 (6.5, 11.8) 94/73 7.9 (6.7, 12.3) 0.88 1.02 (0.76-1.38)
64 8/8 6 (5.9, N.E.) 2/2 5.7 (5.5, N.E.) 0.04 6.06 (0.84-43.74)
66 110/90 6.8 (6.2, 8.5) 87/69 7.1 (6.5, 11.9) 0.49 0.89 (0.65-1.23)
67 35/32 6 (6, 7.2) 19/19 6.3 (6, 7.4) 0.38 1.28 (0.71-2.31)




















Table 4 Clearance of HPV by male circumcision status (Continued)
70 62/53 6.8 (6.2, 11.7) 32/28 6.7 (6.2, 12) 0.54 1.15 (0.73-1.83)
71 54/39 7.5 (6.2, 13) 14/9 7.5 (6, N.E.) 0.53 0.79 (0.38-1.64)
72 49/43 6.1 (6, 7.4) 25/23 6.2 (6, 7.1) 0.35 1.28 (0.76-2.17)
73 49/39 6.2 (6, 9.2) 35/30 7.6 (6.6, 13.6) 0.45 0.83 (0.51-1.33)
81 94/72 7.2 (6.4, 10.3) 39/35 6.6 (6.2, 11.5) 0.29 1.25 (0.83-1.88)
82 30/26 6.2 (6, 11.7) 25/21 6.4 (6.2, 14.2) 0.28 0.73 (0.40-1.32)
83 55/45 6.9 (6, 9.5) 32/25 8 (6.4, 13.9) 0.25 0.75 (0.46-1.22)
84 170/126 7.2 (6.4, 11.4) 131/91 10.4 (6.7, 13.8) 0.07 0.78 (0.60-1.03)
89 166/116 7.2 (6.3, 11.5) 115/88 8.4 (7.7, 12.5) 0.15 0.81 (0.62-1.07)
IS39 31/25 6.2 (6, 13.2) 7/6 13.1 (5.9, N.E.) 0.78 0.87 (0.35-2.12)
aAny HPV was defined as at least one of 37 HPV genotypes;
bOncogenic HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68;
cNon-oncogenic HPV types: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89 (CP6108), and IS39;




















Table 5 Univariate and multivariate hazard ratios for the association between male circumcision and clearance of genital HPV infection
Any HPV Oncogenic HPV Non-Oncogenic HPV
Univariatea Multivariateb Univariatea Multivariatec Univariatea Multivariated
Circumcision Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI)
No 4353/ 5981 72.8 1.00 1.00 1748/ 2266 77.1 1.00 1.00 2605/ 3715 70.1 1.00 1.00
Yes 2548/ 3398 75.0 0.92 (0.86 – 0.99) 0.95 (0.88 – 1.02) 1089/ 1410 77.2 0.86 (0.78 – 0.96) 0.90 (0.81 – 1.00) 1459/ 1988 73.4 0.97 (0.89 – 1.05) 0.98 (0.89 – 1.07)
Total 6901/ 9379 2837/ 3676 4064/ 5703
aAdjusted for age and country;
bCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status;
cCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, lifetime number of male anal sex partners, HPV status at baseline, and six-month visit compliance status;
dCox model stratified by country and age, and adjusted for recent number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status.




















Table 6 Univariate and multivariate hazard ratios for the association between male circumcision and clearance of transient genital HPV infection
Any HPV Oncogenic HPV Non-Oncogenic HPV
Univariatea Multivariateb Univariatea Multivariatec Univariatea Multivariated
Circumcision Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI)
No 2806/ 4434 63.3 1.00 1.00 1106/ 1624 68.1 1.00 1.00 1700/ 2810 60.5 1.00 1.00
Yes 1665/ 2515 66.2 0.95 (0.88 – 1.03) 0.98 (0.90 – 1.06) 745/ 1066 69.9 0.88 (0.77 – 1.00) 0.91 (0.80 – 1.04) 920/ 1449 63.5 0.99 (0.89 – 1.10) 1.01 (0.91 – 1.13)
Total 4471/ 6949 1851/ 2690 2620/ 4259
aAdjusted for age and country;
bCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status;
cCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, lifetime number of male anal sex partners, HPV status at baseline, and six-month visit compliance status;
dCox model stratified by country and age, and adjusted for recent number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status.





















Table 7 Univariate and multivariate hazard ratios for the association between male circumcision and clearance of persistent genital HPV infection
Any HPV Oncogenic HPV Non-Oncogenic HPV
Univariatea Multivariateb Univariatea Multivariatec Univariatea Multivariated
Circumcision Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI) Inf./ Total % HR (95% CI) AHR (95% CI)
No 1474/ 3102 47.5 1.00 1.00 610/ 1128 54.1 1.00 1.00 864/ 1974 43.8 1.00 1.00
Yes 836/ 1686 49.6 0.94 (0.84 – 1.05) 0.99 (0.88 – 1.12) 324/ 645 50.2 0.76 (0.64 – 0.91) 0.84 (0.70 – 1.01) 512/ 1041 49.2 1.07 (0.92 – 1.25) 1.10 (0.94 – 1.29)
Total 2310/ 4788 934/ 1773 1376/ 3015
aAdjusted for age and country;
bCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status;
cCox model stratified by country and age, and adjusted for lifetime number of female sexual partners, lifetime number of male anal sex partners, HPV status at baseline, and six-month visit compliance status;
dCox model stratified by country and age, and adjusted for recent number of female sexual partners, recent number of male anal sex partners, smoking status, HPV status at baseline, and six-month visit
compliance status.





















than among circumcised men for all HR-HPV geno-
types, being statistically significant for HR-HPV types
18 and 33 [2].
No differences in overall HPV clearance by MC were
observed in our study. This finding is in agreement
with findings from other longitudinal studies [4,5].
VanBuskirk et al. [5] found that MC had no effect on
the likelihood of detecting a persistent versus transient
HPV infection over an 8-month period. Hernandez et al.
[4] found that the duration of HPV infection did not
vary by MC for the penile shaft, scrotum, or for all
genital sites combined. However, the median duration of
HPV infection at the glans/coronal sulcus was signifi-
cantly longer in uncircumcised men that in circumcised
men [4]. Similarly, MC increased clearance rates of HR-
HPV infections at the coronal sulcus in the Uganda
RCT [2]. In the study by Lu et al. [3], circumcised men
were more likely to clear infection with any HPV and
oncogenic HPV types using a combined HPV sample
from the coronal sulcus, glans penis, shaft, and scrotum
for HPV detection.
Differences in HPV clearance by MC for certain HPV
types were observed in the present study. Median times
to clearance for HPV types 33 and 64 were significantly
shorter among circumcised men compared to uncircum-
cised men. The RCT in Uganda reported higher rates of
clearance among circumcised men than uncircumcised
men at the coronal sulcus for most HR-HPV types, but
the differences were only statistically significant for HR-
HPV types 39, 51, and 58 [2]. In contrast, we found that
the median times to clearance for HPV types 16, 51, and
6 were significantly longer among circumcised men than
uncircumcised men.
Even though our study was not designed to assess the
effects of MC and HPV by anatomic genital subsite,
there is evidence from the literature that the association
between MC and HPV DNA detection varies according
to the subsite sampled. Four out of five studies show
that the effect of MC in reducing HPV infection is
stronger at the glans/corona than at other, more distant,
subsites [14-18]. Weaver et al. [14], found that HPV
prevalence was significantly lower among circumcised
men (17%) compared to uncircumcised men (32%) on
the glans and foreskin. Interestingly, and consistent with
our findings, when combining results from all subsites,
overall HPV prevalence was similar between circumcised
(31%) and uncircumcised (29%) men. Consistent with
these results, a study by Nielson et al. [15] reported
that HPV prevalence at the glans penis/coronal sul-
cus was significantly lower among circumcised men
(29.8%) compared to uncircumcised men (35.2%). However,
HPV prevalence combining the glans, shaft, and scrotum
was similar in circumcised (48.3%) and uncircumcised
men (44.8%). In another US study, Hernandez et al. [16]
reported a significantly lower HPV prevalence at the
glans penis/coronal sulcus among circumcised men (29%)
compared to uncircumcised men (46%). However, HPV
prevalence at the external genitalia was similar among cir-
cumcised (63%) versus uncircumcised (71%) men. At year 1
in the RCT in Uganda [17], HR-HPV types were more fre-
quently detected on the coronal sulcus than on the penile
shaft among both circumcised and uncircumcised men. In
addition, HR-HPV prevalence at year 1 on the penile cor-
onal sulcus was significantly lower among circumcised men
(21.5%) as compared to uncircumcised men (36.3%).
Finally, a study by Partridge et al. [18], conducted among
male university students in the USA, found that circumci-
sion status was not associated with incident HPV infection
for any of the individual subsites or for all sites combined.
Further supporting the evidence for an effect of MC
on HPV infection on the proximal region of the penis,
three additional studies reported specific inverse associa-
tions between MC and HPV infection in the glans, cor-
onal sulcus, and the distal urethra [19], the glans and
coronal sulcus [20], or the urethra [21].
In addition to the subsites included for HPV DNA de-
tection, several other factors may explain the contrasting
effects observed across studies, such as differences in
participants’ ages, the proportion of circumcised men,
the number of HPV genotypes included in testing, the
time intervals between visits, and the age at which cir-
cumcision was performed.
To our knowledge, this is the first international study
reporting HPV incidence and clearance by specific HPV
types in circumcised and uncircumcised men. With a
sample size of 4,033 men, it is also the largest study ex-
ploring these associations. A key strength of the present
study is its longitudinal design, which allowed repeated
measures of genital HPV DNA status for each partici-
pant, with a median follow-up of 17.5 months and
scheduled visits every six months.
Our study, despite being large, multinational, and pro-
spective, is not free of some limitations, including: (1)
the potential for misclassification of HPV infection, as
we combined samples from different anatomic sub-
sites; (2) the potential for misclassification of prevalent
infections as incident infections, which may inflate the
estimates of cumulative incidence; (3) the possibility of
not distinguishing HPV clearance from failure to detect
a true HPV infection, even though two HPV negative
results following one positive result were required to define
HPV clearance; (4) potentially limited generalizability, as
only men willing to comply with multiple clinical visits over
four years were included in the study; and (5) the potential
for confounding, as there may have been relevant factors
related to religious or cultural practices that may also be as-
sociated with both MC status and HPV incidence or clear-
ance that were not taken into account.
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Conclusions
Overall, our study found that circumcision status was
not associated with incidence and clearance of genital
HPV detection, except for among specific HPV types.
However, the use in this study of a single combined
sample from the penis and scrotum likely limited our
ability to identify a true effect at the distal penis. Further
research is needed to determine how male circumcision
impacts HPV incidence and clearance by specific ana-
tomic subsite and HPV types.
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